These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 10228057

  • 1. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA.
    J Infect Dis; 1999 Jun; 179(6):1375-81. PubMed ID: 10228057
    [Abstract] [Full Text] [Related]

  • 2. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, Moreno S, NELSANE Study.
    AIDS Res Hum Retroviruses; 2001 Jan 20; 17(2):93-8. PubMed ID: 11177388
    [Abstract] [Full Text] [Related]

  • 3. Salvage therapy studies.
    Proj Inf Perspect; 1998 Sep 20; (25):7. PubMed ID: 11365850
    [Abstract] [Full Text] [Related]

  • 4. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M, Salzberger B, Stiepel A, Hoetelmans R, Diehl V, Fätkenheuer G.
    Eur J Med Res; 1999 Feb 25; 4(2):54-8. PubMed ID: 10066640
    [Abstract] [Full Text] [Related]

  • 5. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
    Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D.
    J Infect Dis; 2002 Sep 01; 186(5):626-33. PubMed ID: 12195349
    [Abstract] [Full Text] [Related]

  • 6. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM, Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.
    N Engl J Med; 2003 Sep 11; 349(11):1036-46. PubMed ID: 12968087
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
    Hall CS, Raines CP, Barnett SH, Moore RD, Gallant JE.
    AIDS; 1999 Jul 09; 13(10):1207-12. PubMed ID: 10416524
    [Abstract] [Full Text] [Related]

  • 8. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.
    J Infect Dis; 2001 Jun 15; 183(12):1732-8. PubMed ID: 11372025
    [Abstract] [Full Text] [Related]

  • 9. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 10. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
    Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC.
    J Infect Dis; 1999 Jun 10; 179(6):1356-64. PubMed ID: 10228055
    [Abstract] [Full Text] [Related]

  • 11. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB, Katzenstein TL, Gerstoft J, Mathiesen LR, Pedersen C, Nielsen C.
    Antivir Ther; 2000 Sep 10; 5(3):187-94. PubMed ID: 11075938
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
    Antivir Ther; 2003 Dec 10; 8(6):595-602. PubMed ID: 14760893
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.
    AIDS; 1999 Jul 30; 13(11):F71-7. PubMed ID: 10449277
    [Abstract] [Full Text] [Related]

  • 14. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team.
    N Engl J Med; 2002 Jun 27; 346(26):2039-46. PubMed ID: 12087139
    [Abstract] [Full Text] [Related]

  • 15. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW, AIDS Clinical Trials Group 398 Study Team.
    JAMA; 2002 Jul 10; 288(2):169-80. PubMed ID: 12095381
    [Abstract] [Full Text] [Related]

  • 16. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA.
    J Infect Dis; 2000 Sep 10; 182(3):758-65. PubMed ID: 10950769
    [Abstract] [Full Text] [Related]

  • 17. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
    Rockstroh JK, Altfeld M, Kupfer B, Kaiser R, Fätkenheuer G, Salzberger B, Schneweis KE, Spengler U.
    Eur J Med Res; 1999 Jul 28; 4(7):271-4. PubMed ID: 10425264
    [Abstract] [Full Text] [Related]

  • 18. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E.
    J Infect Dis; 2002 Mar 01; 185(5):599-607. PubMed ID: 11865416
    [Abstract] [Full Text] [Related]

  • 19. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr 01; 8(40):55-60. PubMed ID: 10848067
    [Abstract] [Full Text] [Related]

  • 20. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P, Vibhagool A, Schechter M, Soto-Ramirez L, Carosi G, Smaill F, Jordan JC, Pharo CE, Thomas NE, Steel HM.
    Curr Med Res Opin; 2004 Jul 01; 20(7):1115-23. PubMed ID: 15265256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.